The FDA approves pembrolizumab for high-risk, early-stage TNBC in combination with CT as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
Lack of intrafollicular CD4 expression predicts early failure in FL and combined with FLIPI improves identification of high-risk patients.
Using multiple source databases, study investigators compile a data set including 81 phase II–IV RCTs of patients with non–small-cell lung cancer.
RIC-HSCT yields favorable outcomes for patients with high-risk CLL-RT, especially when performed in early remission.
A new first-line standard of care may be emerging for recurrent or metastatic nasopharyngeal carcinoma, based on the findings of the global phase III JUPITER-02 trial...
The US Preventive Services Task Force has published a final recommendation statement calling for individuals to get their first CRC screening at age 45 instead of waiting until age 50.